{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:15:14Z","timestamp":1784693714573,"version":"3.55.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1074924"],"award-info":[{"award-number":["1074924"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>We describe choice of first\u2010line antihypertensive drug therapy and uptake of fixed\u2010dose combinations (FDCs) in Australia, and investigate the impact of initiation on FDCs and other non\u2010recommended first\u2010line therapies on treatment discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This was a population\u2010based retrospective cohort study using a random 10% sample of persons dispensed an Australian Pharmaceutical Benefits Scheme listed medicine from 1 July 2005 to 30 June 2014. The primary outcomes were adherence to Australian recommendations at initiation of antihypertensive therapy, discontinuation of initial therapy and discontinuation of any therapy in the first year after initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our sample of 55 937 persons initiating therapy, 42.0% did so outside Australian recommendations, including not initiating on recommended monotherapy (26.3%) and not initiating on the lowest recommended dose (30.6%). Only 1.7% of individuals who were dispensed an FDC established therapy on the free combination regimen (as recommended) prior to switching. After adjusting for covariates, persons initiating on non\u2010recommended monotherapy (OR = 2.64, 95% CI 2.47\u20132.83) or FDCs of two or more antihypertensives (OR = 1.42, 95% CI 1.30\u20131.55), were more likely to discontinue all antihypertensive drug treatment in the first year compared to persons initiating on recommended monotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>More than half of antihypertensive initiators conformed to Australian guidelines. Initiation on FDCs and other non\u2010recommended treatments was associated with lower persistence on antihypertensive therapy in the first year. Long\u2010term effectiveness and outcomes may be enhanced by initiating with low dose monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13043","type":"journal-article","created":{"date-parts":[[2016,6,15]],"date-time":"2016-06-15T14:20:31Z","timestamp":1466000431000},"page":"1134-1145","source":"Crossref","is-referenced-by-count":13,"title":["How does prescribing for antihypertensive products stack up against guideline recommendations? An Australian population\u2010based study (2006\u20132014)"],"prefix":"10.1111","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3701-4997","authenticated-orcid":false,"given":"Andrea L.","family":"Schaffer","sequence":"first","affiliation":[{"name":"Centre for Big Data Research in Health University of New South Wales  Sydney NSW 2052 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie\u2010Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health University of New South Wales  Sydney NSW 2052 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Buckley","sequence":"additional","affiliation":[{"name":"Blackburn Building (D06) University of Sydney  Sydney NSW 2006 Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3283282f65"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2008.00019.x"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02388.x"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X273039"},{"key":"e_1_2_9_6_1","first-page":"459","article-title":"Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?","volume":"9","author":"Kaiser EA","year":"2014","journal-title":"Clin Interv Aging"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2011.198"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-007-0340-2"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-015-0562-0"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262453"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802319364"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-124"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja14.00199"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2015.02.016"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1020368"},{"key":"e_1_2_9_17_1","unstructured":"National Heart Foundation of Australia.Guide to management of hypertension 2008(Updated December 2010) [online]. Available athttps:\/\/heartfoundation.org.au\/images\/uploads\/publications\/HypertensionGuidelines2008to2010Update.pdf(last accessed 20 May 2016)."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.05.010"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(00)01310-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.194167"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.201566"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139816"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.596873"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.494462"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2011.00550.x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.534129"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328339f9fa"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.03.017"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2296-9-61"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9782-z"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542290"},{"key":"e_1_2_9_32_1","volume-title":"Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Giudelines 18 and 34 (Internet)","author":"National Clinical Guideline Centre (UK)","year":"2011"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280148a58"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105888"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000003"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2560"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2011.tb03240.x"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.983874"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000011.pub4"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13043","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13043","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:55:39Z","timestamp":1696301739000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/bcp.13043"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13043","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}